Abstract: Objective To evaluate the efficacy and toxicity of rituximab plus CHOP in patients with diffuse large B-cell lymphoma. Methods A total of 48 patients with histopathologically confirmed CD20-positive diffuse large B-cell lymphoma were randomly as-signed into two groups：24 received CHOP plus rituximab（R-CHOP group），and 24 received CHOP alone（CHOP group）.All patients received six chemotherapy cycles，and the therapeutic effect was assessed. Results The overall response rate was 91.7%（22/24） in the R-CHOP group and 66.7%（16/24） in the CHOP group（P<0.05）.The 1-and 3-year survival rates were 95.8% and 83.3% in the R-CHOP group，and 74.7% and 50.0% in the CHOP group.The 1-and 3-year progression-free rates were significantly higher in the R-CHOP group（82.6% and 62.8%） than in the CHOP group（57.3% and 37.2%， P<0.05）.The major side effects in the two groups were myelosuppression，gastrointestinal toxicity and infusion-related adverse reactions.The two groups did not differ significantly in adverse reactions， except chills and fever. Conclusion Combination chemotherapy including Rituximab and CHOP（R-CHOP） is effective and well-tolerated by patients， suggesting it is a good treatment for diffuse large B-cell lymphoma.

Key words: Lymphoma, Rituximab, CHOP regiment, Therapeutic effect